Abstract
Multiple drugs are frequently assumed to induce sexual dysfunction as an unwanted side effect. In this chapter, we review the known mechanisms of sexual function and how the drugs hypothesized to cause sexual dysfunction are thought to interrupt these pathways. The management of drug-induced sexual dysfunction for physicians can be challenging; here, we discuss several management strategies for the treatment of drug-induced sexual dysfunction.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
McVary, K. (2008). Sexual dysfunction. In A. S. B. E. Fauci, D. L. Kasper, S. L. Hauser, D. L. Longo, J. L. Jameson, & J. Loscalzo (Eds.), Harrison’s principles of internal medicine (17th ed.) (pp. 296–300). New York, NY: McGraw-Hill Companies, Inc.
Slag, M. F., Morley, J. E., Elson, M. K., et al. (1983). Impotence in medical clinic outpatients. The Journal of the American Medical Association, 249(13), 1736–1740.
Wein, A. J., & Van Arsdalen, K. N. (1988). Drug-induced male sexual dysfunction. The Urologic Clinics of North America, 15(1), 23–31.
Francis, M. E., Kusek, J. W., Nyberg, L. M., & Eggers, P. W. (2007). The contribution of common medical conditions and drug exposures to erectile dysfunction in adult males. The Journal of Urology, 178(2), 591–596. Discussion 6.
Stadler, T., Bader, M., Uckert, S., Staehler, M., Becker, A., & Stief, C. G. (2006). Adverse effects of drug therapies on male and female sexual function. World Journal of Urology, 24(6), 623–629.
Oger, S., Behr-Roussel, D., Gorny, D., et al. (2008). Combination of alfuzosin and tadalafil exerts in vitro an additive relaxant effect on human corpus cavernosum. The Journal of Sexual Medicine, 5(4), 935–945.
Oger, S., Behr-Roussel, D., Gorny, D., et al. (2009) Combination of doxazosin and sildenafil exerts an additive relaxing effect compared with each compound alone on human cavernosal and prostatic tissue. The Journal of Sexual Medicine, 6(3), 836–47.
Gur, S., Sikka, S. C., Chandra, S., et al. (2008). Alfuzosin attenuates erectile dysfunction in rats with partial bladder outlet obstruction. BJU International, 102(11), 1651–1657.
Gregorian, R. S., Golden, K. A., Bahce, A., Goodman, C., Kwong, W. J., & Khan, Z. M. (2002). Antidepressant-induced sexual dysfunction. The Annals of Pharmacotherapy, 36(10), 1577–1589.
Rosen, R. C., & Marin, H. (2003). Prevalence of antidepressant-associated erectile dysfunction. The Journal of Clinical Psychiatry, 64(Suppl 10), 5–10.
Finkel, M. S., Laghrissi-Thode, F., Pollock, B. G., & Rong, J. (1996). Paroxetine is a novel nitric oxide synthase inhibitor. Psychopharmacology Bulletin, 32(4), 653–658.
Fava, M., Nurnberg, H. G., Seidman, S. N., et al. (2006). Efficacy and safety of sildenafil in men with serotonergic antidepressant-associated erectile dysfunction: Results from a randomized, double-blind, placebo-controlled trial. The Journal of Clinical Psychiatry, 67(2), 240–246.
Nurnberg, H. G., Gelenberg, A., Hargreave, T. B., Harrison, W. M., Siegel, R. L., & Smith, M. D. (2001). Efficacy of sildenafil citrate for the treatment of erectile dysfunction in men taking serotonin reuptake inhibitors. The American Journal of Psychiatry, 158(11), 1926–1928.
Nurnberg, H. G., Hensley, P. L., Gelenberg, A. J., Fava, M., Lauriello, J., & Paine, S. (2003). Treatment of antidepressant-associated sexual dysfunction with sildenafil: A randomized controlled trial. The Journal of the American Medical Association, 289(1), 56–64.
Compton, M. T., & Miller, A. H. (2001). Priapism associated with conventional and atypical antipsychotic medications: A review. The Journal of Clinical Psychiatry, 62(5), 362–366.
Loh, C., Leckband, S. G., Meyer, J. M., & Turner, E. (2004). Risperidone-induced retrograde ejaculation: Case report and review of the literature. International Clinical Psychopharmacology, 19(2), 111–112.
Erdemir, F., Harbin, A., & Hellstrom, W. J. (2008). 5-alpha reductase inhibitors and erectile dysfunction: The connection. The Journal of Sexual Medicine, 5(12), 2917–2924.
Wessells, H., Roy, J., Bannow, J., et al. (2003). Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology, 61(3), 579–584.
Mondaini, N., Gontero, P., Giubilei, G., et al. (2007). Finasteride 5 mg and sexual side effects: How many of these are related to a nocebo phenomenon? The Journal of Sexual Medicine, 4(6), 1708–1712.
Asboe, D., Catalan, J., Mandalia, S., et al. (2007). Sexual dysfunction in HIV-positive men is multi-factorial: A study of prevalence and associated factors. AIDS Care, 19(8), 955–965.
Schrooten, W., Colebunders, R., Youle, M., et al. (2001). Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment. AIDS, 15(8), 1019–1023.
Lamba, H., Goldmeier, D., Mackie, N. E., & Scullard, G. (2004). Antiretroviral therapy is associated with sexual dysfunction and with increased serum oestradiol levels in men. International Journal of STD & AIDS, 15(4), 234–237.
Bhasin, S., Storer, T. W., Javanbakht, M., et al. (2000). Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. The Journal of the American Medical Association, 283(6), 763–770.
Richardson, D., Goldmeier, D., Frize, G., et al. (2007). Letrozole versus testosterone. A single-center pilot study of HIV-infected men who have sex with men on highly active anti-retroviral therapy (HAART) with hypoactive sexual desire disorder and raised estradiol levels. The Journal of Sexual Medicine, 4(2), 502–508.
Scott, J. D., Wolfe, P. R., Anderson, P., Cohan, G. R., & Scarsella, A. (2007). Prospective study of topical testosterone gel (AndroGel) versus intramuscular testosterone in testosterone-deficient HIV-infected men. HIV Clinical Trials, 8(6), 412–420.
Bruckert, E., Giral, P., Heshmati, H. M., & Turpin, G. (1996). Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction. Journal of Clinical Pharmacy & Therapeutics, 21(2), 89–94.
Rizvi, K., Hampson, J. P., & Harvey, J. N. (2002). Do lipid-lowering drugs cause erectile dysfunction? A systematic review. Family Practice, 19(1), 95–98.
Stoll, L. L., McCormick, M. L., Denning, G. M., & Weintraub, N. L. (2004). Antioxidant effects of statins. Drugs Today, 40(12), 975–990.
Penninga, E. I., Larsen, H. K., & Andersen, S. E. (2008). Impotence caused by Methotrexate treatment. Ugeskrift for Laeger, 170(5), 354.
Murphy, P. T., & O’Donnell, J. R. (2007). Thalidomide induced impotence in male hematology patients: A common but ignored complication? Haematologica, 92(10), 1440.
Kraus, M. R., Schafer, A., Bentink, T., et al. (2005). Sexual dysfunction in males with chronic hepatitis C and antiviral therapy: Interferon-induced functional androgen deficiency or depression? The Journal of Endocrinology, 185(2), 345–352.
Huyghe, E., Zairi, A., Nohra, J., Kamar, N., Plante, P., & Rostaing, L. (2007). Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: An overview. Transplant International, 20(4), 305–311.
Freeman, K. (2008). Arsenic and erectile dysfunction: Drinking contaminated well water increases risk. Environmental Health Perspectives, 116(4), A172.
Tostes, R. C., Carneiro, F. S., Lee, A. J., et al. (2008). Cigarette smoking and erectile dysfunction: Focus on NO bioavailability and ROS generation. The Journal of Sexual Medicine, 5(6), 1284–1295.
McVary, K. T., Carrier, S., & Wessells, H. (2001). Smoking and erectile dysfunction: Evidence based analysis. The Journal of Urology, 166(5), 1624–1632.
Harte, C. B., & Meston, C. M. (2008). Acute effects of nicotine on physiological and subjective sexual arousal in nonsmoking men: A randomized, double-blind, placebo-controlled trial. The Journal of Sexual Medicine, 5(1), 110–121.
Aydinoglu, F., Yilmaz, S. N., Coskun, B., Daglioglu, N., & Ogulener, N. (2008). Effects of ethanol treatment on the neurogenic and endothelium-dependent relaxation of corpus cavernosum smooth muscle in the mouse. Pharmacological Reports, 60(5), 725–734.
Bliesener, N., Albrecht, S., Schwager, A., Weckbecker, K., Lichtermann, D., & Klingmuller, D. (2005). Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence. The Journal of Clinical Endocrinology and Metabolism, 90(1), 203–206.
Hallinan, R., Byrne, A., Agho, K., McMahon, C., Tynan, P., & Attia, J. (2008). Erectile dysfunction in men receiving methadone and buprenorphine maintenance treatment. The Journal of Sexual Medicine, 5(3), 684–692.
Hallinan, R., Byrne, A., Agho, K., McMahon, C. G., Tynan, P., & Attia, J. (2007). Hypogonadism in men receiving methadone and buprenorphine maintenance treatment. International Journal of Andrology, 32(2), 131–9.
Aversa, A., Rossi, F., Francomano, D., et al. (2008). Early endothelial dysfunction as a marker of vasculogenic erectile dysfunction in young habitual cannabis users. International Journal of Impotence Research, 20(6), 566–573.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Alphs, H.H., McVary, K.T. (2011). Drugs that Affect Sexual Function. In: McVary, K. (eds) Contemporary Treatment of Erectile Dysfunction. Contemporary Endocrinology. Humana Press. https://doi.org/10.1007/978-1-60327-536-1_7
Download citation
DOI: https://doi.org/10.1007/978-1-60327-536-1_7
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60327-535-4
Online ISBN: 978-1-60327-536-1
eBook Packages: MedicineMedicine (R0)